Somatic alterations of TP53 , ERBB2 , PIK3CA and CCND1 are associated with chemosensitivity for breast cancers

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer

(2016) Juan Miguel Cejalvo et al.   BREAST CANCER RESEARCH AND TREATMENT

Hereditary truncating mutations of DNA repair and other genes inBRCA1/BRCA2/PALB2-negatively tested breast cancer patients

(2016) F. Lhota et al.   CLINICAL GENETICS

BRCA1-2diagnostic workflow from next-generation sequencing technologies to variant identification and final report

(2016) Brunella Pilato et al.   GENES CHROMOSOMES & CANCER

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation

(2016) G. R. Anderson et al.   Science Translational Medicine

A microscopic landscape of the invasive breast cancer genome

(2016) Zheng Ping et al.   Scientific Reports

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

(2015) L. G. Estévez et al.   Clinical & Translational Oncology

Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer

(2015) H. Yuan et al.   CLINICAL CANCER RESEARCH

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer

(2015) Ian J. Majewski et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay

(2015) Kyunghee Park et al.   Oncotarget

p53 as an Effector or Inhibitor of Therapy Response

(2015) Julien Ablain et al.   Cold Spring Harbor Perspectives in Medicine

Frequency of mutations in individuals with breast cancer referred forBRCA1andBRCA2testing using next-generation sequencing with a 25-gene panel

(2014) Nadine Tung et al.   CANCER

Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study

(2014) Vicky S. Sabine et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Cyclin D1 gene amplification is highly homogeneous in breast cancer

(2014) Eike Burandt et al.   Breast Cancer

Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women

(2013) E. Tilch et al.   BREAST CANCER RESEARCH AND TREATMENT

Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines

(2013) Marzieh Badinloo et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility

(2012) V. Theodorou et al.   GENOME RESEARCH

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups

(2011) Alexandra J. van den Broek et al.   BREAST CANCER RESEARCH AND TREATMENT

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

(2011) Soley Bayraktar et al.   BREAST CANCER RESEARCH AND TREATMENT

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer

(2011) Hiroyuki Yasojima et al.   EUROPEAN JOURNAL OF CANCER

RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

(2011) Patrick A. Oberholzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines

(2011) Katrin Tiemann et al.   LEUKEMIA & LYMPHOMA

FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer

(2010) F. Marme et al.   ANNALS OF ONCOLOGY

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer

(2010) Gottfried E. Konecny et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting the RAF–MEK–ERK pathway in cancer therapy

(2009) Clara Montagut et al.   CANCER LETTERS

Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer

(2009) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of Akt Activity by Chemotherapy Confers Acquired Resistance

(2009) Wei-Chien Huang et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

(2008) Priya Rastogi et al.   JOURNAL OF CLINICAL ONCOLOGY